Clinical trials: sponsored by Peking University First Hospital
Encephalitis Autoimmune
Efgartigimod in Anti-NMDA Receptor Encephalitis.
This study is a multicenter, open-label, single-arm exploratory trial designed to enroll 20 eligible patients with anti-NMDAR encephalitis.
- Trial name
- ANSWER (NCT07822776)
- Testing
- Efgartigimod Alfa
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tongren Hospital
SARS-CoV-2 Infection, Hematologic Malignancy
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors
The goal of this observational study is to compare the immune function and infection mechanism of patients with hematologic tumors and those people without underlying diseases after infection with SARS-CoV-2.
- Trial name
- NCT05683353
- Testing
- None intervention
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
IgA Nephropathy (IgAN), Henoch Schönlein Purpura Nephritis
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
The goal of this open-label, randomized study is to evaluate the efficacy and safety of the personalized treatment model in which Gd-IgA1 is dynamically monitored to guide medication adjustment in progressive IgAN patients…
- Trial name
- NCT07822100
- Testing
- Gd-IgA1 monitoring
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Hong Zhang
Multiple Myeloma, Amyloidosis
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study.
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
- Trial name
- NCT05283993
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Breast Cancer Metastatic
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
- Trial name
- NCT05759572
- Testing
- Apatinib, Dalpiciclib, Fulvestrant/AI
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Fudan University
Light Chain (AL) Amyloidosis, MRD
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Before effective treatment, the prognosis of patients with AL amyloidosis is very poor, with a median survival of approximately 12 months.
- Trial name
- NCT07215494
- Testing
- First-Line Dara-BorCyD Treatment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University First Hospital
Rectal Cancer
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
The goal of this clinical trial is to learn about whether it is safe to omit dissection of the No.253 lymph nodes in mid and low rectal cancer surgery.
- Trial name
- NCT06146946
- Testing
- Dissection of the No.253 lymph node, Omitting the dissection of the No.253 lymph node
- Where
- 8 sites in China
- Volunteers
- 1,384 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unresectable Malignant Neoplasm, Bulky Tumor
Proton and Proton-Photon Hybrid Partial Stereotactic Ablative Boost Radiotherapy (P-SABR) for Unresectable Large Tumors
This prospective, multicenter, observational cohort study will enroll 60 adults with unresectable larege tumors (longest diameter > 5 cm) who receive one of two treatment modes: (A) proton P-SABR, in which both the proton…
- Conditions
- Unresectable Malignant Neoplasm, Bulky Tumor, Solid Tumor
- Trial name
- LARGE-Proton (NCT07818798)
- Testing
- Proton P-SABR, Proton-Photon Hybrid P-SABR
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Acute Ischemic Stroke
Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)
This randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human Prourokinase (rhPro-UK) in acute ischemic stroke patients with large vessel…
- Trial name
- NCT07389460
- Testing
- Intravenous rhPro-UK, Endovascular thrombectomy
- Where
- 10 sites in China
- Volunteers
- 820 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
Interleukin-2 (IL-2) is an essential cytokine for T-cell proliferation. Low-dose IL-2 has been shown to increase the proportion of regulatory T cells (Tregs), negatively regulate effector T cells such as Th17 and Tfh cells, and…
- Trial name
- NCT07809724
- Testing
- IL-2 (interleukin 2)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Obstructive Sleep Apnea, Surgery
Mini-dose Dexmedetomidine-Esketamine Supplemented Analgesia in Patients at High-risk of OSA
Patients with obstructive sleep apnea (OSA) are at increased risk of developing sleep disturbances after surgery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, analgesic, and anxiolytic effects.
- Conditions
- Obstructive Sleep Apnea, Surgery, Dexmedetomidine, Esketamine
- Trial name
- NCT06566482
- Testing
- Dexmedetomidine-esketamine combination
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University First Hospital
Hepatocellular Carcinoma (HCC)
GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
This is a diagnostic study. This clinical trial aims to evaluate the diagnostic performance and safety of the novel radiotracer 18F-X12 in patients with hepatocellular carcinoma (HCC), and to provide evidence supporting a new…
- Trial name
- NCT07795437
- Testing
- 18F-X12 PET/CT
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Hematopoietic Stem Cell Transplantation (HSCT), cGVHD
Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD
This prospective, randomized, open-label, multicenter trial aims to compare second-line treatment strategies for hepatic cGVHD after allo-HSCT.
- Conditions
- Hematopoietic Stem Cell Transplantation (HSCT), cGVHD, Hepatic cGVHD, Belumosudil
- Trial name
- NCT07794514
- Testing
- Ruxolitinib treatment, Belumosudil treatment, Belumosudil Switch to Ruxolitinib
- Where
- China
- Volunteers
- 170 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Coronary Artery Disease
FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease
To compare the clinical outcomes of fractional flow reserve (FFR)-guided strategy versus intravascular ultrasound (IVUS)-guided stent implantation after angiography-derived FFR-based decision-making.
- Trial name
- FLAVOUR III (NCT06218485)
- Testing
- Intravascular ultrasound-guided stent implantation after angiography-derived FFR-based decision-making, Fractional flow reserve-guided PCI strategy
- Where
- 32 sites in China, South Korea
- Volunteers
- 1,942 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Nasopharyngeal Carcinoma (NPC), PET / CT
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
This is an observational cohort study designed to (1) evaluate whether Gallium-68 (68Ga)-labeled fibroblast activation protein inhibitor ligand LM3 (68Ga-FAPI-LM3) positron emission tomography/computed tomography (PET/CT)…
- Trial name
- NCT07137052
- Where
- China
- Volunteers
- 732 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy
The goal of this clinical trial is to evaluate the efficacy and safety of Iptacopan as a second-line treatment for high-risk hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA).
- Trial name
- NCT07347990
- Testing
- iptacopan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Depression, Anxiety
Postoperative Anxiety and Depression Among Older Chinese Patients
A multicenter, prospective observational study to describe the socioeconomic characteristics and the occurrence of postoperative anxiety and depression in the Chinese old population.
- Conditions
- Depression, Anxiety, Elderly Patients, Non-cardiac Surgery
- Trial name
- NCT06495840
- Testing
- no intervention
- Where
- China
- Sponsor
- Chinese PLA General Hospital
Lupus Nephritis
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
This is a prospective single-arm multi-center trial to evaluate the efficacy and safety of O-triple regimen in initial active LN patients
- Trial name
- NCT07767188
- Testing
- obinutuzumab (RO5072759)
- Where
- 14 sites in China
- Volunteers
- 70 people
- Sponsor
- Zhao Minghui
Intracranial Aneurysm
General Anesthesia vs Local Anesthesia for Endovascular Treatment in Patients With Unruptured Intracranial Aneurysm Using Flow Diverter
The prevalence of unruptured intracranial aneurysm (UIA) in the population is about 2%-7%, and once it ruptures and bleeds, the rate of disability and death is extremely high, with 10%-15% of patients dying suddenly before they…
- Trial name
- GALA-FD (NCT06416657)
- Testing
- Different anesthesia methods, namely local anesthesia and general anesthesia
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Ming Lv
Tetraplegia, Spinal Cord Injuries (SCI)
A Clinical Trial to Evaluate the Safety and Efficacy of an Implantable Wireless Brain-Computer Interface（BCI）System NEO in Patients With Tetraplegia
To evaluate the safety and efficacy of a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO in patients with tetraplegia and to provide a basis for product registration.
- Trial name
- NEO (NCT06990412)
- Testing
- NEO
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Neuracle Medical Technology(Shanghai) Co.,Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.